All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Alisertib monotherapy for PTCL patients: Results from a phase III trial

By Sylvia Agathou

Share:

Feb 12, 2019


On 1 February 2019, Owen O’Connor from Columbia University Medical Centre, New York, NY, USA and colleagues, published in the Journal of Clinical Oncology a phase III study (LUMIERE) investigating the efficacy of alisertib in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) patients.

Alisertib is an investigational Aurora A kinase inhibitor. Aurora A kinase is involved in cell mitosis and accumulating evidence indicates its pathological upregulation in PTCL. From phase I-II studies the recommended dose and treatment pattern of alisertib monotherapy have been established, together with its promising activity in various lymphomas, including R/R B-cell and T-cell lymphomas. The aim of this randomized, multicenter, two-arm, open-label, phase III trial (NCT01482962) was to investigate the efficacy of alisertib monotherapy versus investigator’s choice treatment in R/R PTCL patients. The primary endpoints of this study were overall response rate (ORR), and progression-free survival (PFS). Secondary endpoints included, overall survival (OS), safety, complete response (CR) rate, time-to-progression (TTP), time-to-partial response (TTR), and duration of response (DoR). 

Study design & baseline characteristics

  • N = 271 R/R PTCL patients after ≥ 1 prior system therapy, aged ≥ 18 were enrolled
  • PTCL subtypes included:
    • PTCL-not otherwise specified (NOS)
    • Anaplastic large-cell lymphoma
    • Angioimmunoblastic T-cell lymphoma
    • Enteropathy associated T-cell lymphoma
    • Hepatosplenic T-cell lymphoma
    • Subcutaneous panniculitis-like T-cell lymphoma
    • Transformed mycosis fungoides
    • Extranodal natural killer/T-cell lymphoma nasal type
  • Patients were stratified according to:
    • Extranodal disease
    • International Prognostic Index (IPI) score:
      • low/intermediate versus intermediate/high
    • Region:
      • North America and European Union versus the rest of the world
    • Patients were randomized in two arms:
      • Alisertib (Arm A; n = 138): orally, 50 mg twice daily on Days 1−7 (21-day cycles)
      • Investigator’s choice monotherapy (Arm B; n = 133), intravenously either of the following:
        • Gemcitabine (n = 30): 1000 mg/m2 over 30 min, on Days 1, 8, and 15 (28-day cycles)
        • Pralatrexate (n = 80): 30 mg/m2 over 3−5 min once weekly for six weeks (7-week cycles)
          • These patients also received vitamin B12 (1 mg every 8−10 weeks) and oral folic acid (1.0−25 mg daily)
        • Romidepsin (n = 23; USA only): 14 mg/m2 over 4 h on Days 1, 8, and 15 (28-day cycles)
      • Alisertib dose reductions with minimum 10 mg decrements per cycle and a maximum of two dose reductions were allowed in case of toxicity
      • Baseline characteristics were well-balanced between the arms
      • Median number or prior lines: 2
      • Data cut-off: 30 June 2015

Key findings

  • In the alisertib arm:
    • Median number of treatment cycles (range) = 4 (0−50) cycles
    • Mean treatment duration (range) = 20.8 (1−148) weeks
    • Mean relative dose intensity = 92.9%
  • In the comparator arm:
    • Median number of treatment cycles (range) = 2 (0−17) cycles
    • Mean treatment duration (range) = 16.6 (1−115) weeks
    • Mean relative dose intensity = 66.1%
  • ORR:
    • Alisertib: 33% (n = 34/102 patients)
    • Comparator arm: 45% (n = 41/92 patients)
    • Comparison: odds ratio = 0.60 (95% CI, 0.33−1.08)
    • Gemcitabine: 35% (n = 8/23)
    • Pralatrexate: 43% (n = 22/51)
    • Romidepsin: 61% (n = 11/18)
  • CR rate:
    • Alisertib: 18%
    • Comparator arm: 27%
  • Although the number of patients in the alisertib and comparator arms were balanced across regions, there was a greater difference in ORR between treatment arms in North America (29%  alisertib versus 59% comparator) than in other regions (Western Europe: 33% versus 36%; rest of world: 36% versus 41%, respectively)
  • Progressive disease (PD) was the most common reason for a PFS event in both arms
  • Median PFS:
    • Alisertib: 115 days
    • Comparators: 104 days
      • Gemcitabine: 57 days
      • Pralatrexate: 101 days
      • Romidepsin: 242 days
    • Comparison: HR = 0.87, (95% CI, 0.644−1.162)
  • Median follow-up duration for OS:
    • Alisertib: 519 days
    • Comparators: 586 days
  • Median OS:
    • Alisertib: 415 days
    • Comparators: 367 days
    • Comparison: HR = 0.98, (95% CI, 0.707−1.369)
  • Twelve-month survival:
    • Alisertib: 53.7%
    • Comparators: 51.5%
  • Twenty-four-month survival:
    • Alisertib: 35%
    • Comparators: 35%
  • Median DoR:
    • Alisertib: 225 days
    • Comparators: 172 days
      • Gemcitabine: 134 days
      • Pralatrexate: 162 days
      • Romidepsin: 473 days
    • Median TTR:
      • Alisertib: 62 days
      • Comparators: 64 days
        • Gemcitabine: 90 days
        • Pralatrexate: 67 days
        • Romidepsin: 61 days
      • Median TTP:
        • Alisertib: 162 days
        • Comparators: 116 days
        • Comparison: HR = 0.95, (95% CI, 0.679−1.329)
      • At 24 months, patients who had not experienced PD:
        • Alisertib: 12.8%
        • Comparators: 14.3%
      • Median time to subsequent antineoplactic therapy:
        • Alisertib: 336 days
        • Comparators: 233 days
          • Gemcitabine: 144 days
          • Pralatrexate: 233 days
          • Romidepsin: not estimable
        • Comparison: HR = 0.98, (95% CI, 0.692−1.385)

Safety

  • Most common any cause Grade ≥ 3 adverse events (AEs; alisertib versus comparators):
    • Neutropenia: 43% versus 25%
    • Thrombocytopenia: 29% versus 27%
    • Anemia: 33% versus 11%
  • Most common treatment-emergent AEs (TEAEs; alisertib versus comparators):
    • Neutropenia: 45% versus 30%
    • Thrombocytopenia: 34% versus 38%
    • Anemia: 43% versus 24%
    • Diarrhea: 32% versus 19%
    • Stomatitis: 31% versus 42%
  • Serious AEs occurred in:
    • Alisertib: 55%
    • Comparators: 54%
  • Overall, 26 study deaths occurred (alisertib, 11 [8%]; comparators, 15 [12%])
    • Of these, n = 3 in the alisertib and n = 1 in the comparator arm were drug-related

Conclusions

  • Alisertib did not lead to superior outcomes (PFS, ORR) versus comparator drugs (gemcitabine, pralatrexate or romidepsin) when administered to R/R PTCL patients

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?